Syed Sami, MD
Interventional Pain Medicine · Saginaw, MINPI 1023345782
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,081 of the $2,861 with a category attached, or 72.7%. 23 manufacturers reported payments, led by Abbott at 59.2% of the total. Reporting peaked in 2022 at $1,340 and has fallen 90.4% since, to $129 in 2023.
Across 115 payments — averaging $24.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- AstraZeneca$216
- Sunovion Pharmaceuticals Inc.$170
- Indivior Inc.$113
- Orexo US, Inc.$93
- Pfizer$71
- plus $506 from 17 others
What the payments were for
- Travel & lodging$69424%
- Food & beverage$2,08173%
- Education$873%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 54 | $1,694 |
| AstraZeneca | 4 | $216 |
| Sunovion Pharmaceuticals Inc. | 14 | $170 |
| Indivior Inc. | 6 | $113 |
| Orexo US, Inc. | 7 | $93 |
| Pfizer | 3 | $71 |
| AbbVie(2 entities) | 4 | $63 |
| Zimmer Biomet | 1 | $51 |
| Kowa Pharmaceuticals America, Inc. | 3 | $50 |
| Amgen(2 entities) | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Si-bone, Inc. | 1 | $35 |
| GSK | 2 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $27 |
| GRT US Holding, Inc. | 2 | $25 |
| Avanir Pharmaceuticals, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $23 |
| Alkermes, Inc. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Biodelivery Sciences International, Inc. | 1 | $12 |
| Endo Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,861 in reported general payments places this provider in the 60th percentile of 88 interventional pain medicine providers in Michigan.
See all interventional pain medicine providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 33 | $30,584 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 212 | $19,581 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 28 | $17,837 |
| EliquisApixaban | 17 | $16,528 |
| MovantikNaloxegol Oxalate | 32 | $16,289 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 981 | $12,209 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 346 | $5,439 |
| Oxycodone Hcl | 60 | $3,283 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 78 | $2,645 |
| Morphine Sulfate ErMorphine Sulfate | 102 | $2,233 |
| Morphine Sulfate | 63 | $1,321 |
| Diclofenac Sodium | 59 | $1,315 |
| Ventolin HfaAlbuterol Sulfate | 18 | $914 |
| Gabapentin | 132 | $794 |
| Losartan Potassium | 58 | $608 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $63 | $30,58433 claims |
| Orexo US, Inc.Zubsolv | $93 | $17,83728 claims |
| PfizerEliquis | $71 | $16,52817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 88 interventional pain medicine providers in Michigan.
Other interventional pain medicine in Saginaw
- Michael PapenfuseSaginaw$6K
- Ryan PollinaSaint Clair Shores$144K
- Ariel MajjhooMonroe$124K
- Chad BrummettAnn Arbor$109K
- Anand ThakurClinton Township$102K
- Evan PeskinFlint$72K
- Richard FerroLansing$31K
- John ChatasAnn Arbor$29K
- Bryant IttiaraAllen Park$28K
- Fadi DellyWyandotte$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.